Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934228 | 0.84 | SMN1; SMN2 (0.61) | ALDH1A1MAPK1MMP3SMN1; SMN2EPHX2 | |
| SCHEMBL25902481 | 0.78 | MAPK1 (0.48) | ALDH1A1MAPK1MMP3SMN1; SMN2EPHX2 | |
| SCHEMBL8302189 | 0.77 | SMN1; SMN2 (0.46) | ALDH1A1MAPK1SMN1; SMN2LMNAPTPN1 | |
| SCHEMBL14805378 | 0.75 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2LMNAHTTPTPN1 | |
| SCHEMBL24279552 | 0.75 | MAPT (0.50) | ALDH1A1SMN1; SMN2LMNAPOLBMMP2 | |
| SCHEMBL4935297 | 0.72 | EPHX2 (0.58) | ALDH1A1MAPK1MMP3SMN1; SMN2EPHX2 | |
| SCHEMBL12330823 | 0.69 | EPHX2 (0.69) | ALDH1A1MAPK1EPHX2RAB9A | |
| SCHEMBL3910101 | 0.68 | GAA (0.53) | ALDH1A1MAPK1MMP3SMN1; SMN2EPHX2 | |
| SCHEMBL19553789 | 0.67 | EPHX2 (0.51) | ALDH1A1MAPK1EPHX2 | |
| 1,4-Diisopentoxybenzene SCHEMBL2846102 | 0.67 | TDP1 (0.79) | ALDH1A1MAPK1MMP3SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED | 2008-09-18 | — | — | US | disclosed |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED | 2008-09-18 | — | — | US | disclosed |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED | 2008-09-18 | — | — | US | disclosed |
| US-7375248-B2 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2008-05-20 | — | — | US | disclosed |
| US-7375248-B2 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2008-05-20 | — | — | US | disclosed |
| US-7375248-B2 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2008-05-20 | — | — | US | disclosed |
| US-20060142385-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| WO-2004113279-A1 | INHIBITORS OF MATRIX METALLOPROTEINASE | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142385-A1 | Inhibitors of matrix metalloproteinase | MMP9, MMP13, MMP26 | ALDH1A1 3385/4885MAPK1 2761/4885MMP3 14/4885 |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | MMP9, MMP13, MMP2 | ALDH1A1 3221/4885MAPK1 2950/4885MMP3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.